1. A 58-year-old man on atorvastatin 40 mg reports bilateral thigh aching for three weeks. His creatine kinase (CK) level is 6 times the upper limit of normal (ULN). He has no weakness and his urine is clear. Which of the following correctly classifies this presentation within the spectrum of statin-associated muscle symptoms (SAMS)?
A) Rhabdomyolysis, because any CK elevation above 5× ULN in a statin-treated patient constitutes a medical emergency requiring immediate drug discontinuation and hospitalization
B) Myalgia, because the patient has muscle symptoms without any detectable CK elevation — CK levels in myalgia are by definition normal
C) Myopathy, because the patient has muscle symptoms accompanied by CK elevation greater than 10× ULN — wait, at 6× ULN this patient does not yet meet the myopathy threshold and occupies an intermediate symptomatic zone
D) Statin-associated autoimmune myopathy (SAAM), because bilateral proximal muscle symptoms in a statin-treated patient are the defining feature of the autoimmune syndrome regardless of CK level
E) Rhabdomyolysis, because CK elevation of any magnitude combined with muscle pain in a statin-treated patient satisfies the clinical definition of rhabdomyolysis
ANSWER: C
Rationale:
This question establishes the foundational vocabulary of the SAMS spectrum. The correct classification is the intermediate symptomatic zone — the patient has muscle symptoms with CK elevation, but at 6× ULN he does not meet the formal threshold for myopathy, which requires CK elevation greater than 10× ULN. Myalgia (the most common SAMS presentation) is defined as muscle pain, aching, tenderness, stiffness, or weakness without CK elevation — option B is therefore wrong because this patient does have a CK elevation.
Option A: Option A is incorrect because rhabdomyolysis requires CK elevation typically greater than 40× ULN accompanied by myoglobinuria and risk of acute kidney injury — a CK of 6× ULN does not satisfy this threshold, and the 5× ULN cutoff stated in option A is not the clinical definition of rhabdomyolysis.
Option D: Option D is incorrect because SAAM is a rare immune-mediated necrotizing myopathy characterized by anti-HMGCR antibodies and a course that persists or worsens after statin discontinuation — it is not diagnosed on the basis of bilateral symptoms alone regardless of CK level.
Option E: Option E is incorrect because CK elevation of any magnitude does not satisfy the clinical definition of rhabdomyolysis — the threshold is typically greater than 40× ULN, not any detectable elevation. The clinical implication of this patient's presentation is careful monitoring: his CK is elevated but below the myopathy threshold, his symptoms are present but manageable, and the appropriate response is dose reduction or a switch to a less myotoxic statin rather than immediate discontinuation or hospitalization.
2. A clinical pharmacology lecturer asks her students why the reported rate of muscle symptoms in patients taking statins is so much higher in open-label observational studies (5–20%) than in blinded randomized controlled trials (1–5%). Which of the following best explains this discrepancy?
A) The nocebo effect — patients who know they are taking a statin and have been warned about muscle side effects are more likely to attribute pre-existing or nonspecific muscle discomfort to the drug, inflating the reported rate in unblinded settings
B) Selection bias — randomized controlled trials deliberately exclude patients with any prior muscle complaints, selecting a low-risk population that is not representative of the general statin-treated population
C) Reporting bias — investigators in industry-sponsored blinded trials systematically suppress muscle symptom reports to protect favorable trial outcomes, whereas open-label studies have no such incentive
D) Pharmacokinetic differences — patients in open-label studies are typically prescribed higher statin doses than those enrolled in blinded trials, directly increasing the pharmacological rate of muscle toxicity
E) Ascertainment bias — open-label studies use more sensitive CK-based screening protocols that detect subclinical myopathy invisible to blinded trial endpoints, which rely only on patient-reported symptoms
ANSWER: A
Rationale:
This question teaches one of the most clinically important concepts in statin pharmacology — the nocebo effect explains why the publicly perceived rate of statin muscle toxicity dramatically exceeds the pharmacologically real rate. When patients know they are taking a statin and have been counseled about muscle side effects, they are primed to attribute any muscle aching, stiffness, or fatigue — symptoms that are extremely common in middle-aged and older adults for many other reasons — to the drug. In blinded conditions where neither the patient nor the investigator knows whether a statin or placebo is being taken, muscle symptom rates in the statin arm are not significantly different from placebo in most large trials. This is the operational definition of the nocebo effect: an adverse outcome caused by the expectation of harm rather than by a pharmacological action of the drug. Option B is partially true — trials do have inclusion and exclusion criteria — but this alone does not account for the magnitude of the discrepancy or explain why placebo arms in blinded trials show nearly identical rates. Option C is not supported by evidence; blinded trial methodology prevents selective suppression of patient-reported outcomes.
Option D: Option D is incorrect — clinical trials frequently use doses equivalent to or higher than outpatient practice.
Option E: Option E inverts the ascertainment logic; blinded trials use standardized symptom reporting that is actually more rigorous than retrospective open-label follow-up.
3. A 62-year-old woman on simvastatin 40 mg presents with severe proximal muscle weakness, dark tea-colored urine, and a creatine kinase (CK) level of 52 times the upper limit of normal (ULN). Her serum creatinine has risen from her baseline of 0.9 mg/dL to 2.4 mg/dL over 48 hours. Which of the following correctly identifies her diagnosis and its defining features?
A) Severe myopathy — defined as CK elevation greater than 10× ULN with muscle weakness; her CK of 52× ULN places her at the extreme end of this category, and dark urine is a non-specific finding that does not change the classification
B) Rhabdomyolysis — defined by CK elevation typically greater than 40× ULN, myoglobinuria producing the characteristic dark urine, and risk of acute kidney injury from myoglobin-mediated tubular toxicity, all of which are present here
C) Statin-associated autoimmune myopathy (SAAM) — the combination of proximal muscle weakness, markedly elevated CK, and renal involvement is pathognomonic for the immune-mediated necrotizing myopathy triggered by statin exposure
D) Myalgia with incidental renal impairment — CK elevation reflects muscle inflammation but does not by itself indicate true muscle fiber destruction; the renal impairment is likely a coincidental finding unrelated to the statin
E) Gemfibrozil-statin interaction syndrome — severe rhabdomyolysis in a statin-treated patient is almost always attributable to concurrent fibrate use and cannot be classified as statin-induced rhabdomyolysis without pharmacokinetic confirmation of a drug interaction
ANSWER: B
Rationale:
This question teaches the diagnostic criteria for rhabdomyolysis as the most severe end of the SAMS spectrum. The three defining features are present: CK elevation typically greater than 40× ULN (her value of 52× ULN satisfies this threshold), myoglobinuria producing the characteristic tea-colored or cola-colored urine from filtered myoglobin, and acute kidney injury from myoglobin precipitation and direct tubular toxicity. Myoglobin-mediated acute kidney injury is the primary life-threatening complication of rhabdomyolysis and requires aggressive intravenous fluid resuscitation to maintain urine output and prevent tubular precipitation. Option E is a distractor based on a true pharmacology principle — gemfibrozil does increase statin myopathy risk through OATP1B1 and UGT inhibition — but rhabdomyolysis does occur with statin monotherapy and does not require fibrate co-administration for classification.
Option A: Option A incorrectly classifies the presentation as severe myopathy — the dark urine and renal impairment are not non-specific findings; they are the hallmark complications that elevate this beyond myopathy into rhabdomyolysis.
Option C: Option C is incorrect because SAAM is an immune-mediated condition defined by anti-HMGCR antibodies and a course that persists after statin discontinuation — it does not present with acute-onset rhabdomyolysis and myoglobinuria.
Option D: Option D incorrectly minimizes the significance of the CK elevation and renal impairment — a CK of 52× ULN indicates massive muscle fiber destruction, and the temporal relationship with the CK elevation makes statin-associated rhabdomyolysis the correct diagnosis.
4. A 55-year-old man on rosuvastatin 20 mg develops proximal limb weakness and a CK of 28 times the upper limit of normal (ULN). Rosuvastatin is discontinued, but eight weeks later his weakness has worsened and his CK has risen to 45× ULN. Anti-HMGCR (anti-3-hydroxy-3-methylglutaryl coenzyme A reductase) antibodies return strongly positive. Which of the following best describes this condition and its management implication?
A) Statin-associated rhabdomyolysis with delayed recovery — rhabdomyolysis frequently requires 8–12 weeks for CK normalization after statin discontinuation, and continued CK elevation with worsening weakness during this window is an expected part of the natural recovery course
B) Statin rechallenge phenomenon — rebound myopathy after statin discontinuation is caused by upregulation of HMG-CoA reductase expression during statin therapy, which produces paradoxical myotoxicity when the inhibitory drug is removed
C) Gemfibrozil interaction myopathy — persistent post-discontinuation myopathy is characteristic of the gemfibrozil-statin interaction because gemfibrozil irreversibly inhibits statin glucuronidation, producing sustained statin accumulation that outlasts drug discontinuation by weeks
D) Severe myopathy with expected spontaneous resolution — CK elevation greater than 10× ULN with weakness always resolves within 12 weeks of statin discontinuation without specific therapy, and watchful waiting is appropriate even in the setting of worsening symptoms
E) Statin-associated autoimmune myopathy (SAAM) — an immune-mediated necrotizing myopathy that is triggered by statin exposure but driven by anti-HMGCR antibodies in a self-sustaining autoimmune process that persists and worsens after statin discontinuation and requires immunosuppressive therapy
ANSWER: E
Rationale:
This question teaches the single most important distinguishing feature of SAAM: it does not resolve when the statin is stopped. Conventional statin-associated muscle toxicity — myalgia, myopathy, and even rhabdomyolysis — resolves within weeks of drug discontinuation because the toxicity is pharmacologically mediated and ceases when the drug is cleared. SAAM is categorically different: the statin triggers an autoimmune response in which anti-HMGCR antibodies drive ongoing immune-mediated necrosis of muscle fibers through a self-sustaining mechanism that is independent of continued statin exposure. Anti-HMGCR antibodies are both sensitive and specific for this condition and confirm the diagnosis in the appropriate clinical context. Management requires immunosuppressive therapy — typically corticosteroids as first-line, with methotrexate, azathioprine, or intravenous immunoglobulin (IVIG) added for refractory or severe cases. This is not a condition where watchful waiting is appropriate.
Option A: Option A is incorrect — progressive worsening of weakness and rising CK eight weeks after statin discontinuation is not a feature of normal rhabdomyolysis recovery; it is a red flag requiring immediate re-evaluation.
Option B: Option B fabricates a rebound mechanism that does not exist.
Option C: Option C is incorrect because gemfibrozil inhibition is pharmacokinetic and reversible, not a mechanism for persistent post-discontinuation myopathy.
Option D: Option D is incorrect because worsening symptoms after drug removal are never appropriate for watchful waiting without establishing a diagnosis.
5. Which of the following antibodies is the defining serological marker of statin-associated autoimmune myopathy (SAAM), and what is its diagnostic significance?
A) Anti-Jo-1 antibody — a myositis-specific antibody that identifies the antisynthetase syndrome, which is the most common immune-mediated myopathy triggered by statin exposure and the primary diagnostic target in suspected SAAM
B) Anti-SRP (signal recognition particle) antibody — the antibody most commonly elevated in statin-triggered immune myopathy, reflecting the role of the signal recognition particle pathway in HMG-CoA reductase protein trafficking in skeletal muscle
C) Anti-HMGCR (anti-3-hydroxy-3-methylglutaryl coenzyme A reductase) antibody — the defining marker of SAAM, directed against the statin's own pharmacological target enzyme, and both sensitive and specific for immune-mediated necrotizing myopathy in the appropriate clinical context
D) Anti-Mi-2 antibody — a dermatomyositis-specific antibody that cross-reacts with HMG-CoA reductase epitopes exposed during statin-induced enzyme upregulation, producing the necrotizing myopathy pattern characteristic of SAAM
E) Anti-MDA5 antibody — the antibody associated with rapidly progressive interstitial lung disease in inflammatory myopathy, which co-occurs with muscle involvement in approximately 40% of statin-triggered autoimmune myopathy cases
ANSWER: C
Rationale:
This question targets the serological identity of SAAM. Anti-HMGCR antibodies are directed against the enzyme that statins inhibit — HMG-CoA reductase — and are both sensitive and specific for immune-mediated necrotizing myopathy in patients with statin exposure. The autoimmune mechanism is thought to involve statin-induced upregulation of HMG-CoA reductase expression in genetically susceptible individuals, which increases presentation of reductase-derived peptides to the immune system and triggers antibody formation. Once established, the antibody response drives ongoing muscle fiber necrosis independently of continued statin exposure — which is why discontinuation alone does not resolve SAAM. Anti-Jo-1 (option A) is the antibody of the antisynthetase syndrome — a distinct inflammatory myopathy associated with interstitial lung disease, mechanic's hands, and Raynaud phenomenon — not SAAM. Anti-SRP (option B) is associated with a severe necrotizing myopathy that is not statin-specific and does not target HMG-CoA reductase. Anti-Mi-2 (option D) is a dermatomyositis-specific antibody; the cross-reactivity mechanism described is fabricated. Anti-MDA5 (option E) is associated with amyopathic dermatomyositis and rapidly progressive interstitial lung disease — the 40% co-occurrence figure described is not accurate for statin-triggered cases and the association is fabricated for this distractor.
6. A first-year resident asks her attending why the package inserts for statins still mention liver toxicity warnings when she has heard that routine liver function monitoring is no longer recommended. Which of the following most accurately characterizes the evidence on statin hepatotoxicity?
A) Statins cause dose-dependent progressive hepatic fibrosis in approximately 5–10% of treated patients over five years, which is why hepatic ultrasound rather than aminotransferase monitoring is now recommended as the preferred surveillance method
B) True clinically significant statin-induced liver injury is rare — occurring at approximately 1–3 per 100,000 patient-years — and asymptomatic aminotransferase elevations greater than 3 times the upper limit of normal occur in approximately 0.5–3% of patients but are dose-dependent, self-limited, and not predictive of progression to clinical hepatitis or liver failure
C) Statins are directly hepatotoxic at therapeutic doses in all patients, but the liver's regenerative capacity prevents clinical injury in the majority — only patients with underlying hepatic disease manifest overt hepatotoxicity because their regenerative reserve is insufficient to compensate
D) Statin hepatotoxicity was a major clinical problem through the 1990s but has been essentially eliminated by the removal of cerivastatin from the market in 2001, and currently marketed statins carry no meaningful liver injury risk at any dose
E) Routine aminotransferase monitoring remains the standard of care for statin-treated patients and is recommended at baseline, at 3 months, and annually thereafter by all major guidelines because subclinical hepatic injury precedes overt toxicity by 6–12 months in susceptible individuals
ANSWER: B
Rationale:
This question addresses one of the most clinically important evidence-practice gaps in statin pharmacology. The historical concern that statins cause clinically significant liver injury has been substantially overstated, and this has led to outdated monitoring practices that persist in clinical culture despite strong evidence to the contrary. True statin-associated idiosyncratic drug-induced liver injury (DILI) occurs at approximately 1–3 per 100,000 patient-years — a rate comparable to many other commonly prescribed medications. No large randomized controlled trial has demonstrated statin-induced liver failure at rates above placebo. Asymptomatic ALT or AST elevations greater than 3× ULN do occur in approximately 0.5–3% of patients and are dose-dependent, but they reflect a non-specific hepatocellular response to statin metabolism rather than true hepatotoxicity — they are self-limited, typically resolve with dose reduction or discontinuation, and do not predict progression to clinical hepatitis or liver failure.
Option A: Option A is incorrect — statins do not cause progressive hepatic fibrosis at therapeutic doses.
Option C: Option C is incorrect — statins are not universally hepatotoxic; the mechanism described is fabricated.
Option D: Option D incorrectly attributes the resolution of hepatotoxicity concerns solely to cerivastatin's withdrawal; cerivastatin's problem was myopathy, not hepatotoxicity, and current statins do carry a small but real liver injury signal.
Option E: Option E is incorrect — in 2012 the FDA revised statin labeling to remove the recommendation for routine periodic liver enzyme monitoring, citing the lack of evidence that monitoring detects or prevents clinically meaningful liver injury.
7. In 2012, the FDA revised the prescribing information for all statins with respect to liver enzyme monitoring. Which of the following correctly describes that revision and its clinical rationale?
A) The FDA mandated that baseline alanine aminotransferase (ALT) testing be performed before initiating any statin, and that follow-up testing be performed at 6 weeks, 3 months, and 6 months after initiation — a more rigorous schedule than the prior annual monitoring recommendation
B) The FDA required all statin manufacturers to add a black-box warning about hepatotoxicity and to implement a Risk Evaluation and Mitigation Strategy (REMS) program requiring prescriber certification before statin initiation
C) The FDA withdrew approval for lovastatin and simvastatin at doses above 40 mg due to confirmed hepatotoxicity at high doses and redirected prescribers to lower-dose regimens with annual aminotransferase monitoring
D) The FDA removed the recommendation for routine periodic liver enzyme monitoring during statin therapy, citing the lack of evidence that monitoring detects or prevents clinically meaningful liver injury — baseline testing before initiation remains appropriate but routine follow-up monitoring is no longer required
E) The FDA approved a hepatoprotective co-administration protocol requiring ursodeoxycholic acid supplementation in all patients receiving high-intensity statin therapy to mitigate the hepatotoxicity risk documented in post-marketing surveillance
ANSWER: D
Rationale:
This question tests direct knowledge of a clinically significant regulatory change that updated statin prescribing practice. In 2012, the FDA revised statin labels to remove the prior recommendation for routine periodic liver function testing during statin therapy. The rationale was straightforward: no evidence demonstrated that routine monitoring detected clinically meaningful liver injury at a stage where intervention would change outcomes, and the high rate of asymptomatic, self-limited aminotransferase elevations was generating unnecessary statin discontinuation in patients who would have benefited from continued therapy. Baseline aminotransferase measurement before initiating statin therapy remains clinically reasonable to establish a reference point, particularly in patients with risk factors for liver disease. Repeat testing should be prompted by symptoms — jaundice, right upper quadrant pain, fatigue — rather than performed on a fixed schedule in asymptomatic patients.
Option A: Option A describes a more intensive monitoring schedule than ever existed in clinical guidelines — it is fabricated.
Option B: Option B is incorrect — no statin carries a black-box warning for hepatotoxicity, and no REMS program exists for statins based on liver toxicity.
Option C: Option C is incorrect — lovastatin and simvastatin dose restrictions introduced in 2011 were based on myopathy risk with drug interactions, not hepatotoxicity.
Option E: Option E describes a protocol that does not exist in any guideline or FDA action.
8. A 52-year-old man with nonalcoholic fatty liver disease (NAFLD) and mildly elevated ALT at 2.1 times the upper limit of normal (ULN) has an LDL-C of 148 mg/dL and a calculated 10-year ASCVD risk of 14%. His gastroenterologist has told him he should not take statins because of his liver disease. Which of the following best reflects current evidence and guidelines regarding statin use in this patient?
A) Statins are not contraindicated in NAFLD — available evidence suggests statins do not worsen hepatic steatosis or fibrosis and may reduce hepatic inflammation; this patient's cardiovascular risk justifies statin therapy, and mildly elevated baseline aminotransferases do not constitute a contraindication
B) Statins are absolutely contraindicated in any patient with elevated aminotransferases regardless of cause, because pharmacokinetic modeling demonstrates that impaired hepatic metabolism increases statin systemic exposure to hepatotoxic concentrations in patients with pre-existing liver disease
C) Statins can be used in NAFLD only if aminotransferases are below 1.5 times the upper limit of normal and hepatic biopsy has confirmed the absence of bridging fibrosis, because progressive fibrosis dramatically increases statin hepatotoxicity risk
D) The gastroenterologist's advice is correct — NAFLD represents a state of impaired hepatic statin clearance that increases plasma statin concentrations twofold to threefold, and the FDA label for all statins lists active liver disease and unexplained persistent aminotransferase elevations as absolute contraindications that apply to NAFLD
E) Statins should be withheld in NAFLD until aminotransferases normalize spontaneously or after lifestyle intervention, because initiating statin therapy during a period of active hepatic inflammation produces irreversible mitochondrial toxicity that cannot be detected by aminotransferase monitoring alone
ANSWER: A
Rationale:
This question addresses a very common clinical misconception that causes real harm — the withholding of evidence-based cardiovascular therapy from patients with NAFLD based on unfounded hepatotoxicity concerns. The available evidence consistently shows that statins do not worsen hepatic steatosis, inflammation, or fibrosis in NAFLD patients, and several studies suggest potential hepatoprotective effects through anti-inflammatory and antifibrotic mechanisms. This patient has a 14% 10-year ASCVD risk — squarely in the intermediate-to-high risk category where statin therapy provides clear cardiovascular mortality benefit — and mildly elevated aminotransferases at 2.1× ULN do not constitute a contraindication to statin therapy. The FDA label language about active liver disease and unexplained persistent aminotransferase elevations was written to address severe hepatic impairment and has historically been misapplied to NAFLD, which is neither active inflammatory liver disease in the traditional sense nor unexplained. Option C applies a biopsy threshold that does not exist in any guideline. Option D misrepresents the FDA label and overstates the pharmacokinetic consequence of NAFLD.
Option B: Option B is incorrect — the pharmacokinetic premise is overstated; mild NAFLD does not produce clinically significant impairment of hepatic statin clearance.
Option E: Option E describes irreversible mitochondrial toxicity from statin use in active hepatic inflammation — this mechanism is not supported by clinical evidence or pharmacological data.
9. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) enrolled patients with low LDL-C but elevated high-sensitivity C-reactive protein (hsCRP) and randomized them to rosuvastatin 20 mg or placebo. Which of the following findings from JUPITER first clearly established the association between statin therapy and new-onset type 2 diabetes mellitus?
A) Rosuvastatin increased fasting plasma glucose by an average of 22 mg/dL compared to placebo across the entire enrolled population, with glucose elevations occurring within the first 4 weeks of therapy — before any meaningful LDL-C reduction — confirming a direct pancreatic beta-cell mechanism
B) Rosuvastatin produced a 14% relative increase in new-onset diabetes compared to placebo, an effect confined entirely to patients with body mass index (BMI) greater than 35 kg/m² — suggesting that statin-associated diabetes is exclusively an obesity-mediated phenomenon
C) Rosuvastatin increased new-onset diabetes by 52% compared to placebo in the JUPITER population, an effect that completely offset the cardiovascular benefit of rosuvastatin and led the trial steering committee to recommend against statin use in primary prevention populations with any metabolic risk factors
D) Rosuvastatin produced no statistically significant increase in new-onset diabetes in the overall JUPITER population, but a significant 31% increase was detected in a pre-specified subgroup with baseline impaired fasting glucose — establishing that only patients with pre-existing dysglycemia are at risk
E) Rosuvastatin increased new-onset diabetes by approximately 27% compared to placebo in the JUPITER population, a finding that generated debate about whether the cardiovascular benefit of rosuvastatin outweighed the metabolic risk, particularly in patients with pre-existing metabolic risk factors
ANSWER: E
Rationale:
The JUPITER trial was the first large randomized controlled trial to clearly demonstrate a statistically significant increase in new-onset type 2 diabetes with statin therapy. Rosuvastatin 20 mg increased new-onset diabetes by approximately 27% compared to placebo — a relative risk that was statistically significant and clinically notable given the large trial size. This finding generated substantial discussion about risk-benefit balance: the same trial demonstrated a 44% relative reduction in the primary cardiovascular composite endpoint, and subsequent analyses showed that the cardiovascular benefit substantially outweighed the diabetes risk in numerical terms, particularly in patients without metabolic risk factors at baseline. However, JUPITER's enrollment specifically included patients with at least one metabolic risk factor in many cases (elevated waist circumference, impaired fasting glucose, hypertension, or low HDL-C), and the diabetes signal was concentrated in this metabolically vulnerable subgroup.
Option A: Option A is incorrect — the 22 mg/dL glucose elevation figure and the 4-week timeline are fabricated; statins do not produce acute pancreatic toxicity on that timeline.
Option B: Option B understates the diabetes increase (14% vs the actual 27%) and incorrectly restricts the effect to BMI >35 — the diabetes signal was broader than this.
Option C: Option C overstates the diabetes increase (52%) and misrepresents the trial steering committee's conclusions; the trial reported a net cardiovascular benefit.
Option D: Option D is incorrect — the overall JUPITER population did show a statistically significant increase in new-onset diabetes, not only in a subgroup with impaired fasting glucose.
10. The Cholesterol Treatment Trialists (CTT) Collaboration conducted a meta-analysis of large statin trials to quantify the risk of new-onset type 2 diabetes mellitus (NODM) associated with statin therapy. Which of the following most accurately summarizes the CTT findings on this risk?
A) The CTT meta-analysis found no statistically significant increase in new-onset diabetes with any statin regimen — the JUPITER signal was attributed to a trial-specific enrollment bias, and pooled data across all major trials showed diabetes incidence indistinguishable from placebo
B) The CTT meta-analysis estimated that high-intensity statin therapy increases new-onset diabetes risk by approximately 12% relative to placebo, while moderate-intensity therapy increases risk by approximately 10%, translating in absolute terms to roughly 1 additional diabetes case per 250–500 patients treated for 4 years
C) The CTT meta-analysis found that the diabetogenic effect of statins was entirely explained by weight gain — patients on high-intensity statins gained an average of 2.4 kg more than placebo-treated patients, and after adjusting for weight the diabetes signal disappeared completely
D) The CTT meta-analysis found a 38% relative increase in new-onset diabetes with high-intensity statin therapy, an effect large enough that the collaboration recommended restricting high-intensity statins to secondary prevention patients in whom cardiovascular benefit clearly exceeded the metabolic risk
E) The CTT meta-analysis confirmed that the diabetogenic risk of statins is class-specific — rosuvastatin and atorvastatin were associated with a 22–28% relative increase in NODM, while pravastatin, fluvastatin, and pitavastatin showed no significant diabetes signal, supporting selective use of neutral-glycemic statins in metabolically vulnerable patients
ANSWER: B
Rationale:
This question establishes the CTT quantification of statin-associated diabetes risk — the most authoritative pooled estimate available. The CTT Collaboration meta-analysis of major statin trials found that high-intensity statin therapy produces approximately a 12% relative increase in new-onset diabetes compared to placebo, with moderate-intensity therapy producing approximately a 10% relative increase. Expressed as absolute risk, these relative increases translate to approximately 1 additional case of diabetes per 250–500 patients treated for 4 years — a clinically meaningful but modest absolute risk increment that must be weighed against the cardiovascular mortality benefit, which is substantially larger in high-risk patients. This framing — relative vs. absolute risk — is central to communicating statin benefit-risk to patients and is tested throughout the upper tiers. Option C introduces a weight-gain mechanism that is not supported by the CTT analysis; the diabetogenic effect of statins is not explained by weight change.
Option A: Option A incorrectly dismisses the diabetes signal entirely — the CTT did find a statistically significant increase across pooled data.
Option D: Option D overstates the relative risk (38% vs the actual ~12%) and misrepresents the CTT's recommendations — the collaboration did not recommend restricting high-intensity statins to secondary prevention only.
Option E: Option E overstates the statin class specificity of the diabetes signal; while some data suggest pitavastatin may be more glycemically neutral, the CTT analysis does not support the clean class separation described.
11. A 61-year-old woman with hypertension, a 10-year ASCVD risk of 18%, and no prior diabetes is about to start high-intensity statin therapy. She has read online that statins cause diabetes and asks her physician to quantify the risk. Which of the following most accurately conveys the absolute risk of new-onset diabetes from high-intensity statin therapy as estimated in large trial meta-analyses?
A) High-intensity statin therapy increases the absolute risk of new-onset diabetes by approximately 8–12% over 4 years — meaning that roughly 1 in 10 patients treated will develop diabetes as a direct consequence of statin therapy, a risk that substantially narrows the net cardiovascular benefit in primary prevention populations
B) The absolute risk of new-onset diabetes from statin therapy is negligible and can be disregarded in patient counseling — no randomized controlled trial has demonstrated a statistically significant increase in clinically diagnosed diabetes with statin therapy when intention-to-treat analysis is applied
C) High-intensity statin therapy increases the absolute risk of new-onset diabetes by approximately 0.2–0.4% per year, translating to roughly 1 additional case of diabetes per 250–500 patients treated over 4 years — a clinically meaningful but modest absolute increment that is substantially outweighed by cardiovascular mortality benefit in high-risk patients
D) The absolute risk of new-onset diabetes from high-intensity statin therapy is approximately 3–5% over 4 years — comparable to the cardiovascular event reduction in intermediate-risk primary prevention patients, meaning the diabetogenic risk nearly offsets the cardiovascular benefit in this population
E) Statin-associated diabetes risk applies only to patients who already have impaired fasting glucose at baseline — patients with normal fasting glucose have zero absolute risk increment, and the population-level diabetes signal reflects entirely the acceleration of diabetes in pre-diabetic individuals rather than de novo induction
ANSWER: C
Rationale:
This question teaches the absolute risk framing that is essential for accurate patient counseling about statin-associated diabetes. The relative risk increase of approximately 12% from high-intensity statin therapy sounds alarming in isolation but translates to a very modest absolute risk increment: approximately 1 additional case of diabetes per 250–500 patients treated over 4 years, or roughly 0.2–0.4% per year. This number must be placed in context — a high-intensity statin in a patient with 18% 10-year ASCVD risk prevents cardiovascular events at a rate that substantially exceeds the diabetes harm in absolute terms. The net benefit favors statin therapy in this patient. Furthermore, the diabetes that does occur in statin-treated patients tends to arise in patients who were already at high metabolic risk — those with impaired fasting glucose, obesity, metabolic syndrome, or family history — rather than in metabolically normal individuals. Option A dramatically overstates the absolute risk — 8–12% is the relative risk increase, not the absolute risk; applying the relative risk figure as an absolute percentage is a fundamental statistical error.
Option B: Option B incorrectly dismisses the diabetes signal entirely — it is statistically robust in major trials and meta-analyses.
Option D: Option D overstates the absolute risk at 3–5% and incorrectly implies near-equivalence with cardiovascular benefit.
Option E: Option E overstates the exclusivity of diabetes risk to pre-diabetic patients — while metabolically vulnerable patients carry higher risk, the absolute increment is not zero in metabolically normal patients.
12. Which of the following patient profiles carries the highest absolute risk of developing new-onset diabetes mellitus during statin therapy, based on the clinical factors identified in large statin trial analyses?
A) A 45-year-old male marathon runner with LDL-C of 162 mg/dL, fasting glucose of 82 mg/dL, BMI of 22 kg/m², HDL-C of 68 mg/dL, and no family history of diabetes — initiated on rosuvastatin 20 mg for primary prevention based on elevated 10-year ASCVD risk from smoking history
B) A 38-year-old woman with familial hypercholesterolemia, LDL-C of 310 mg/dL, normal fasting glucose, BMI of 21 kg/m², no hypertension, and no family history of diabetes — initiated on high-intensity atorvastatin therapy to reduce LDL-C toward target
C) A 55-year-old man with isolated hypertriglyceridemia, normal LDL-C, fasting glucose of 88 mg/dL, and BMI of 24 kg/m² — initiated on moderate-intensity statin therapy because elevated triglycerides were felt to indicate elevated cardiovascular risk
D) A 59-year-old woman with fasting glucose of 108 mg/dL (prediabetes), BMI of 31 kg/m², waist circumference of 94 cm, HDL-C of 38 mg/dL, triglycerides of 195 mg/dL, and hypertension — initiated on high-intensity atorvastatin for an LDL-C of 142 mg/dL and 10-year ASCVD risk of 16%
E) A 48-year-old man with heterozygous familial hypercholesterolemia, LDL-C of 245 mg/dL, fasting glucose of 79 mg/dL, BMI of 23 kg/m², and no features of metabolic syndrome — initiated on rosuvastatin 40 mg plus ezetimibe for LDL-C reduction
ANSWER: D
Rationale:
This question applies the metabolic risk factor framework to identify the patient most vulnerable to statin-associated new-onset diabetes. The patient in option D has four established risk factors for statin-associated diabetes: prediabetes (fasting glucose 108 mg/dL, which meets the impaired fasting glucose threshold of 100–125 mg/dL), obesity (BMI 31 kg/m²), features of metabolic syndrome (elevated waist circumference, low HDL-C, elevated triglycerides, hypertension), and high-intensity statin therapy. Each of these factors independently increases the absolute risk of statin-associated diabetes, and their co-occurrence in a single patient substantially amplifies the risk. The clinical implication is not to withhold statin therapy — her 10-year ASCVD risk of 16% and LDL-C of 142 mg/dL justify treatment — but to counsel her explicitly about diabetes risk, optimize lifestyle interventions, and monitor fasting glucose more closely after initiation.
Option A: Option A is incorrect because that patient has a normal fasting glucose of 82 mg/dL, healthy BMI of 22 kg/m², high HDL-C, and no metabolic syndrome features — this metabolically normal profile confers the lowest absolute risk of statin-associated diabetes in the group.
Option B: Option B is incorrect because that patient has normal fasting glucose, BMI of 21 kg/m², no hypertension, and no family history of diabetes — familial hypercholesterolemia does not itself increase statin-associated diabetes risk.
Option C: Option C is incorrect because that patient has a normal fasting glucose of 88 mg/dL and BMI of 24 kg/m² with no metabolic syndrome features — isolated hypertriglyceridemia without other metabolic risk factors does not substantially increase statin-associated diabetes risk.
Option E: Option E is incorrect because that patient has a fasting glucose of 79 mg/dL, BMI of 23 kg/m², and no features of metabolic syndrome — heterozygous familial hypercholesterolemia with a metabolically normal profile does not confer elevated diabetes risk from statin therapy.
13. A 67-year-old man with stage 3b chronic kidney disease (CKD) — estimated glomerular filtration rate (eGFR) of 38 mL/min/1.73m² — has an LDL-C of 136 mg/dL and a calculated 10-year ASCVD risk of 22%. His internist is uncertain whether statin therapy is safe and effective in CKD. Which of the following most accurately reflects current evidence and prescribing guidance for statin use in non-dialysis CKD?
A) Statins are appropriate in non-dialysis CKD and have demonstrated cardiovascular benefit in this population — the SHARP (Study of Heart and Renal Protection) trial showed that simvastatin plus ezetimibe significantly reduced major atherosclerotic events in patients with CKD, including those with eGFR below 60 mL/min/1.73m²; dose adjustment is required for renally cleared statins in severe CKD
B) Statins are contraindicated in all patients with eGFR below 45 mL/min/1.73m² because reduced renal clearance of active statin metabolites produces a threefold to fivefold increase in plasma statin concentrations, leading to unacceptable myopathy and hepatotoxicity rates in this population
C) Statins are not effective in CKD because uremia suppresses hepatic LDL receptor upregulation — the primary mechanism by which statins lower LDL-C — making the drug class pharmacodynamically ineffective below an eGFR threshold of approximately 45 mL/min/1.73m²
D) Statins are appropriate in CKD only if the patient has established ASCVD — primary prevention statin use in CKD is not supported by any randomized controlled trial evidence and is not recommended by KDIGO or ACC/AHA guidelines for patients with eGFR below 60 mL/min/1.73m²
E) All statins are equally appropriate in severe CKD and no dose adjustment is required because statins undergo exclusively hepatic elimination with no renally cleared active metabolites — renal impairment does not affect statin pharmacokinetics in a clinically meaningful way
ANSWER: A
Rationale:
This question establishes the evidence base for statin use in non-dialysis CKD. The SHARP trial is the landmark evidence: it randomized approximately 9,000 patients with CKD — including both pre-dialysis and dialysis patients — to simvastatin 20 mg plus ezetimibe 10 mg or placebo, and demonstrated a significant 17% relative reduction in major atherosclerotic events in the pre-dialysis CKD population. This established that statins reduce cardiovascular events in CKD patients and that the pharmacodynamic effect of LDL-C lowering is preserved in non-dialysis CKD. Regarding prescribing specifics, dose adjustment is important for renally cleared statins: rosuvastatin should be initiated at lower doses in severe CKD (eGFR <30 mL/min/1.73m²); pravastatin and fluvastatin are considered safer in severe CKD because they have minimal active renal metabolite accumulation.
Option B: Option B is incorrect — statins are not contraindicated in eGFR <45 mL/min/1.73m², and the threefold to fivefold plasma concentration increase described is not a class effect.
Option C: Option C is incorrect — uremia does not abolish hepatic LDL receptor upregulation by statins; the pharmacodynamic mechanism remains operative in CKD.
Option D: Option D overstates the primary prevention restriction; KDIGO 2013 guidelines recommend statin initiation in adults aged 50 and older with CKD not on dialysis regardless of ASCVD status.
Option E: Option E is incorrect — rosuvastatin does have renally cleared active metabolites and requires dose adjustment in severe CKD; the claim that all statins require no dose adjustment in CKD is incorrect.
14. A 71-year-old woman with end-stage renal disease (ESRD) on hemodialysis three times weekly has an LDL-C of 118 mg/dL. She has no prior cardiovascular events. Her nephrologist tells her that statins are not routinely initiated in dialysis patients. Which of the following best explains the evidence basis for this recommendation?
A) Statins are contraindicated in dialysis patients because hemodialysis membranes adsorb statin molecules from the plasma during dialysis sessions, producing unpredictable plasma concentration fluctuations that make dose titration impossible and increase myopathy risk through peak-dose toxicity
B) Statins are withheld in dialysis patients solely for pharmacoeconomic reasons — large dialysis center contracts with insurers exclude statin coverage, and the recommendation reflects a reimbursement policy rather than a pharmacological or clinical rationale
C) Statins reduce LDL-C effectively in dialysis patients but are withheld because the class causes irreversible acceleration of vascular calcification in the uremic milieu — a mechanism that converts the atheroprotective LDL-C reduction into net cardiovascular harm in ESRD
D) Statins have not been shown to reduce cardiovascular events in dialysis patients in randomized controlled trials — the 4D trial (atorvastatin in type 2 diabetic hemodialysis patients) and the AURORA trial (rosuvastatin in dialysis patients) both failed to demonstrate significant reductions in major cardiovascular endpoints despite effective LDL-C lowering
E) Dialysis patients on statins showed a paradoxical increase in cardiovascular mortality in both the 4D and AURORA trials — a finding attributed to immune activation by statin-induced reduction of isoprenoid intermediates that are required for normal T-cell function in uremic patients — leading to a formal FDA contraindication for statin use in dialysis-dependent ESRD
ANSWER: D
Rationale:
This question addresses one of the most counterintuitive findings in cardiovascular pharmacology — the failure of statins to reduce cardiovascular events in dialysis-dependent patients despite effective LDL-C lowering. Two large randomized controlled trials established this: the 4D trial randomized approximately 1,200 type 2 diabetic hemodialysis patients to atorvastatin 20 mg or placebo and found no significant reduction in the primary cardiovascular composite endpoint; the AURORA trial randomized approximately 2,700 dialysis patients to rosuvastatin 10 mg or placebo with the same negative result. The SHARP trial corroborated this pattern — while the pre-dialysis CKD subgroup benefited significantly, the dialysis subgroup did not demonstrate the same event reduction. The mechanistic explanation for this disconnect is not fully established but likely relates to the different nature of cardiovascular disease in ESRD: sudden cardiac death, arrhythmia, and cardiac arrest — driven by uremic cardiomyopathy, electrolyte disturbances, and vascular calcification — account for a larger proportion of cardiovascular mortality in dialysis patients than classic atherothrombotic events, which are the events most responsive to LDL-C lowering. The clinical implication is that statins are not routinely initiated in dialysis patients, though patients already on statins at the time of dialysis initiation may continue therapy.
Option A: Option A fabricates a hemodialysis membrane adsorption mechanism that does not exist.
Option B: Option B is incorrect — the recommendation is evidence-based, not reimbursement-driven.
Option C: Option C fabricates a statin-induced vascular calcification mechanism in uremia that is not supported by evidence.
Option E: Option E overstates the 4D and AURORA findings — neither trial found a statistically significant increase in cardiovascular mortality, and there is no FDA contraindication for statin use in dialysis patients.
15. A 31-year-old woman with heterozygous familial hypercholesterolemia (HeFH) on rosuvastatin 20 mg discovers she is 7 weeks pregnant. Her LDL-C has been well controlled at 98 mg/dL on this regimen. What is the correct immediate management regarding her statin therapy?
A) Rosuvastatin should be continued throughout the first trimester only, because the teratogenic risk of statins is confined to organogenesis in the first trimester — after 14 weeks gestation, statin use is safe and necessary to prevent placental vascular complications of uncontrolled hypercholesterolemia in familial hypercholesterolemia patients
B) Rosuvastatin must be discontinued immediately — statins are contraindicated throughout pregnancy because cholesterol and its biosynthetic precursors are essential for fetal development, and inhibition of the mevalonate pathway during gestation carries teratogenic risk supported by animal studies and human case reports
C) Rosuvastatin can be continued safely because familial hypercholesterolemia represents a high-risk exception to the general statin-pregnancy contraindication — untreated LDL-C levels in HeFH patients during pregnancy carry a higher risk of maternal cardiovascular events than the fetal teratogenic risk from continued statin exposure
D) Rosuvastatin should be switched to pravastatin, which is the only statin with a pregnancy Category B designation — pravastatin's hydrophilic properties prevent placental transfer and make it the preferred statin for use throughout pregnancy in women with familial hypercholesterolemia
E) Statin therapy should be continued at the current dose, and the patient should be referred to a maternal-fetal medicine specialist — current ACC/AHA guidelines endorse individualized statin continuation in HeFH patients during the second and third trimesters under specialist supervision
ANSWER: B
Rationale:
This question establishes the categorical contraindication of statins in pregnancy — one of the most important prescribing safety rules in this drug class. Statins inhibit HMG-CoA reductase and thereby suppress the mevalonate pathway, which is the biosynthetic source not only of cholesterol but also of isoprenoid intermediates (farnesyl pyrophosphate, geranylgeranyl pyrophosphate) and ubiquinone (CoQ10) that are essential for fetal cell growth, differentiation, and membrane synthesis. Animal studies with multiple statins have demonstrated skeletal malformations, CNS anomalies, and fetal death. Human case reports have associated statin exposure during pregnancy with limb defects and CNS malformations, though causality in humans is complicated by the rarity of statin use in pregnant women and confounding factors. On this basis, statins were historically classified as FDA Pregnancy Category X — contraindicated in pregnancy — and while the FDA replaced categorical pregnancy labeling with the current narrative labeling system in 2015, the contraindication language in statin prescribing information has been retained. The correct action is immediate discontinuation.
Option A: Option A is incorrect — there is no safe window for statin use in pregnancy; the contraindication applies throughout gestation.
Option C: Option C is incorrect — familial hypercholesterolemia does not constitute an exception; no guideline endorses statin continuation in HeFH during pregnancy.
Option D: Option D is incorrect — pravastatin does not carry a Category B designation; no statin has ever been classified as safe in pregnancy, and pravastatin's hydrophilicity does not confer fetal safety.
Option E: Option E is incorrect — no current ACC/AHA guideline endorses statin continuation during the second or third trimester under any circumstances.
16. An 81-year-old man with a history of myocardial infarction three years ago, hypertension, and type 2 diabetes asks his cardiologist whether he should continue his atorvastatin 40 mg — his daughter has told him that statins are not appropriate for patients over 80. Which of the following most accurately reflects current evidence and guideline recommendations for statin therapy in older adults?
A) Statins should be routinely discontinued at age 75 in all patients regardless of ASCVD history because the benefit-risk ratio invariably shifts unfavorable after this age — the increased myopathy risk from age-related sarcopenia and polypharmacy drug interactions in elderly patients outweighs any residual cardiovascular benefit
B) Statin therapy is not beneficial in patients over 75 because atherosclerotic cardiovascular disease in this age group is driven primarily by calcific and inflammatory mechanisms rather than LDL-C-mediated plaque growth — LDL-C lowering does not reduce events in this population regardless of baseline LDL-C level
C) In patients over 75 with established ASCVD, the cardiovascular benefit of statin therapy is well established and continuation is appropriate — age alone is not a reason to discontinue a statin in a patient with prior myocardial infarction; the evidence for primary prevention statin use in adults over 75 without established ASCVD is less certain and requires individualized assessment
D) Statins must be dose-reduced by 50% in all patients over 75 regardless of renal or hepatic function because age-related reduction in CYP3A4 and CYP2C9 hepatic enzyme activity produces clinically significant statin accumulation that routinely causes myopathy at standard doses in elderly patients
E) Statin therapy in patients over 75 should be guided exclusively by frailty status — robust elderly patients may continue at full dose, but any patient who screens positive on a frailty instrument must have statin therapy discontinued to prevent falls, rhabdomyolysis, and drug-drug interactions in a polypharmacy context
ANSWER: C
Rationale:
This question addresses a clinically common and consequential scenario — the inappropriate discontinuation of evidence-based secondary prevention therapy based on age alone. In patients over 75 with established ASCVD, the cardiovascular benefit of statin therapy is well established and supported by both randomized trial data and guideline recommendations. This patient — 81 years old with a prior myocardial infarction — is exactly the population in whom secondary prevention statin therapy has demonstrated the greatest absolute benefit, because his high baseline cardiovascular event rate means that a given relative risk reduction translates to a larger absolute risk reduction than in younger, lower-risk primary prevention patients. Age alone is not a reason to discontinue statin therapy in a patient with established ASCVD. The situation is more nuanced for primary prevention statin use in adults over 75 without established ASCVD — here the evidence base is less robust, randomized trial data are limited, competing mortality risks may attenuate cardiovascular benefit, and individualized assessment of life expectancy, frailty, polypharmacy, and patient preferences is appropriate. The 2018 ACC/AHA guideline acknowledges this distinction explicitly.
Option A: Option A is incorrect — there is no guideline recommendation to discontinue statins at age 75; this is a common myth with real clinical harm.
Option B: Option B is incorrect — LDL-C-mediated atherosclerosis remains the dominant mechanism of ASCVD in elderly patients, and statin therapy reduces events in this age group.
Option D: Option D is incorrect — age-related CYP enzyme decline does not mandate a universal 50% dose reduction; this recommendation does not exist in any guideline.
Option E: Option E is incorrect — frailty is a relevant clinical consideration but is not the sole determinant of statin continuation; discontinuing statins exclusively on frailty screening without considering ASCVD history is not guideline-concordant.
17. A 54-year-old man with no prior muscle disease, no interacting medications, and normal renal and hepatic function is about to start atorvastatin 40 mg for primary prevention. Which of the following most accurately reflects current recommendations regarding creatine kinase (CK) monitoring before and during statin therapy?
A) CK should be measured at baseline, at 6 weeks after initiation, and every 6 months thereafter in all statin-treated patients regardless of symptoms — early detection of subclinical myopathy before symptom onset is the primary rationale for this surveillance schedule, and rising CK without symptoms is an indication to reduce the statin dose
B) CK measurement is not recommended at baseline or at any point during statin therapy in any patient — CK testing is considered a legacy monitoring practice that was never supported by randomized trial evidence and has been formally removed from all major guideline recommendations
C) CK should be measured at baseline in all patients initiating statin therapy; if baseline CK is greater than 3 times the upper limit of normal before statin initiation, statin therapy is absolutely contraindicated and must not be initiated regardless of cardiovascular risk
D) Routine baseline CK measurement is not required in low-risk patients without predisposing factors for myopathy; it is reasonable in patients with risk factors such as personal or family history of muscle disease, high-intensity physical activity, or interacting medications — routine CK monitoring during therapy is not recommended in asymptomatic patients, and CK testing should be prompted by symptoms rather than performed on a fixed schedule
E) CK must be measured within 72 hours of statin initiation in all patients to establish a true pharmacological baseline — pre-treatment CK values obtained more than 2 weeks before drug initiation are pharmacokinetically invalid because statin-mediated muscle effects begin within hours of the first dose and alter subsequent CK interpretation
ANSWER: D
Rationale:
This question establishes the current evidence-based approach to CK monitoring in statin therapy. Routine pre-treatment CK measurement is not required in low-risk patients — the patient in this question has no personal or family history of muscle disease, no interacting medications, and no other predisposing factors, so a baseline CK is not mandated. Baseline CK measurement is clinically reasonable in patients with identifiable risk factors for statin myopathy: personal or family history of muscle disease or statin intolerance, concomitant use of interacting drugs (fibrates, especially gemfibrozil; azole antifungals; certain macrolides), high-intensity endurance exercise, hypothyroidism, or significant renal or hepatic impairment. During therapy, routine CK monitoring in asymptomatic patients is not recommended — the yield of detecting actionable subclinical myopathy in the absence of symptoms is low, and serial CK testing generates incidental abnormalities that prompt unnecessary statin discontinuation. CK testing should be symptom-driven: any patient reporting muscle aching, weakness, or tenderness warrants CK measurement to classify the SAMS presentation and guide management. Option B goes too far in the opposite direction — baseline CK in high-risk patients is reasonable and is not discouraged.
Option A: Option A describes a systematic surveillance schedule that is not recommended by ACC/AHA or other major guidelines.
Option C: Option C overstates the contraindication threshold — a pre-treatment CK of 3× ULN is not an absolute contraindication; the threshold for withholding statin initiation is generally CK greater than 4× or 5× ULN on repeat testing in a symptomatic patient.
Option E: Option E fabricates a 72-hour initiation window with no pharmacological basis.
18. A 63-year-old woman on simvastatin 40 mg develops myalgia — bilateral leg aching without CK elevation — that resolves within two weeks of stopping the drug. She requires LDL-C lowering for established ASCVD. Which of the following is the most appropriate next step in managing her statin intolerance?
A) After resolution of symptoms, rechallenge with a different statin at a lower dose — rosuvastatin and pravastatin are preferred for rechallenge because their hydrophilicity reduces skeletal muscle uptake relative to lipophilic statins; alternate-day dosing of rosuvastatin is a validated strategy in patients with dose-limiting myalgia that allows effective LDL-C lowering with reduced symptom burden
B) Permanently discontinue all statin therapy and transition to ezetimibe monotherapy as the sole lipid-lowering agent — the development of any muscle symptoms on a statin, even without CK elevation, constitutes a class-wide contraindication to further statin use and no rechallenge is appropriate
C) Rechallenge with the same simvastatin 40 mg regimen after a 4-week washout — if symptoms recur, this confirms a true pharmacological statin effect, and the patient should then receive a 6-month trial of coenzyme Q10 (ubiquinol) supplementation before abandoning statin therapy
D) Switch immediately to a PCSK9 inhibitor (proprotein convertase subtilisin/kexin type 9 inhibitor) as first-line replacement therapy — PCSK9 inhibitors have no mechanism-related muscle toxicity and are the guideline-recommended first-line alternative in any patient who develops myalgia on a statin regardless of severity
E) Confirm nocebo effect by administering a blinded statin rechallenge under double-blind placebo-controlled conditions — current ACC/AHA guidelines recommend that all patients with suspected statin myalgia undergo formal blinded rechallenge in a clinical research setting before the diagnosis of statin intolerance is accepted
ANSWER: A
Rationale:
This question teaches the practical management strategy for statin intolerance — one of the most common clinical challenges in lipid pharmacology. Myalgia without CK elevation (the mildest end of the SAMS spectrum) that resolves with drug discontinuation is the most manageable form of statin intolerance, and the goal is always to find a tolerated statin regimen rather than abandon the drug class entirely, because statin therapy provides outcomes data that no other agent class fully replicates in established ASCVD. The standard approach is rechallenge with a different statin — preferably a hydrophilic statin such as rosuvastatin or pravastatin, which have reduced skeletal muscle uptake compared to lipophilic agents such as simvastatin, atorvastatin, and lovastatin. Alternate-day dosing of rosuvastatin (taking advantage of its long half-life of approximately 20 hours and its persistent LDL receptor upregulation effect) is a well-validated strategy for patients with dose-limiting myalgia — it reduces peak muscle exposure while maintaining meaningful LDL-C lowering. Option C recommends restarting the same offending drug and introducing CoQ10 supplementation — CoQ10 supplementation has not been shown in randomized controlled trials to reduce statin-associated myalgia and is not guideline-recommended.
Option B: Option B incorrectly establishes a class-wide contraindication from a single episode of myalgia without CK elevation — this is the most harmful misconception in statin intolerance management and results in patients with established ASCVD being denied effective secondary prevention therapy.
Option D: Option D incorrectly positions PCSK9 inhibitors as first-line replacements for statin myalgia — guidelines recommend optimizing statin therapy (dose, agent, frequency) before escalating to PCSK9 inhibitors, which are reserved for patients who remain above LDL-C targets on maximally tolerated statin therapy.
Option E: Option E describes a formal blinded rechallenge protocol that does not exist as a guideline recommendation for routine clinical practice.
19. Which of the following best explains why hydrophilic statins such as rosuvastatin and pravastatin are associated with a lower risk of statin-associated muscle symptoms (SAMS) compared to lipophilic statins such as simvastatin and lovastatin?
A) Hydrophilic statins are selective inhibitors of the hepatic isoform of HMG-CoA reductase, which differs in amino acid sequence from the skeletal muscle isoform — lipophilic statins inhibit both isoforms equally, producing direct pharmacodynamic suppression of mevalonate synthesis in muscle cells that hydrophilic statins avoid
B) Hydrophilic statins have limited passive diffusion across cell membranes and enter hepatocytes primarily via active organic anion transporter (OATP1B1/1B3) uptake — this selective hepatic uptake reduces their distribution into skeletal muscle relative to lipophilic statins, which passively diffuse into muscle cells and produce higher intramuscular concentrations of drug and active metabolites
C) Hydrophilic statins are metabolized exclusively by UGT (uridine diphosphate glucuronosyltransferase) glucuronidation rather than CYP450 pathways — this non-CYP metabolism eliminates the drug interactions responsible for myopathy, because all clinically significant statin drug interactions occur through CYP450-mediated mechanisms
D) Hydrophilic statins produce lower peak plasma concentrations than lipophilic statins at equivalent doses because their lower oral bioavailability results in greater first-pass intestinal metabolism — the reduced peak concentration directly limits the concentration gradient driving muscle uptake
E) Hydrophilic statins have shorter half-lives than lipophilic statins, which limits their duration of muscle exposure — pravastatin has a half-life of approximately 1–2 hours compared to simvastatin's 12-hour half-life, meaning that daily dosing of pravastatin produces less cumulative muscle exposure per week than simvastatin
ANSWER: B
Rationale:
This question teaches the pharmacokinetic basis for differential SAMS risk between hydrophilic and lipophilic statins. The key distinction is the mechanism of cellular entry: lipophilic statins (simvastatin, lovastatin, atorvastatin, fluvastatin) can passively diffuse across the phospholipid bilayer of any cell membrane — including skeletal muscle cell membranes — because their lipophilicity allows them to partition into the hydrophobic core of the membrane. Hydrophilic statins (rosuvastatin, pravastatin) cannot efficiently cross cell membranes by passive diffusion and instead enter hepatocytes primarily through active transport via OATP1B1 and OATP1B3 (organic anion transporting polypeptides) expressed on the hepatocyte sinusoidal membrane. This selective hepatic uptake means that rosuvastatin and pravastatin achieve high intracellular concentrations in hepatocytes — where HMG-CoA reductase inhibition produces the desired LDL-lowering effect — while achieving substantially lower intracellular concentrations in skeletal muscle, reducing direct muscle toxicity.
Option A: Option A fabricates a tissue-isoform selectivity of HMG-CoA reductase — there is a single HMG-CoA reductase gene and both hydrophilic and lipophilic statins inhibit the same enzyme.
Option C: Option C is incorrect — hydrophilic statins are not exclusively UGT-metabolized; rosuvastatin undergoes minor CYP2C9 metabolism, and the claim that all statin interactions are CYP-mediated is wrong because OATP1B1 inhibition by gemfibrozil is a major non-CYP interaction mechanism.
Option D: Option D is incorrect — hydrophilic statins do not have lower bioavailability as a class; the SAMS risk difference is driven by distribution into muscle, not by peak plasma concentrations.
Option E: Option E is incorrect — rosuvastatin actually has a longer half-life (approximately 19–20 hours) than pravastatin (approximately 1–2 hours), and the SAMS advantage of hydrophilic statins is not attributable to half-life differences.
20. A 58-year-old man on simvastatin 20 mg is started on gemfibrozil for hypertriglyceridemia. Three weeks later he develops diffuse muscle pain and his CK is 18 times the upper limit of normal (ULN). Which of the following best explains the pharmacological mechanism responsible for this interaction?
A) Gemfibrozil activates peroxisome proliferator-activated receptor alpha (PPAR-alpha) in skeletal muscle, which upregulates fatty acid oxidation and suppresses glucose utilization — the resulting energetic shift in muscle metabolism sensitizes myocytes to statin-induced CoQ10 depletion and amplifies the myotoxic effect
B) Gemfibrozil competitively inhibits the CYP3A4 enzyme responsible for simvastatin metabolism in the intestinal wall and liver, producing a threefold to fivefold increase in simvastatin AUC (area under the plasma concentration-time curve) — an effect comparable in magnitude to the azole antifungal interaction
C) Gemfibrozil induces hepatic CYP2C9, which converts simvastatin acid to a reactive epoxide metabolite with direct mitochondrial toxicity in skeletal muscle — a metabolic activation pathway not shared by fenofibrate, which explains the fibrate class differential in myopathy risk
D) Gemfibrozil displaces simvastatin from plasma protein binding sites, acutely increasing free simvastatin concentration by 8–12 fold — the free fraction enters skeletal muscle by passive diffusion at a rate proportional to the unbound plasma concentration, producing rapid intramuscular drug accumulation
E) Gemfibrozil inhibits OATP1B1 (organic anion transporting polypeptide 1B1) hepatic uptake transporters and inhibits UGT (uridine diphosphate glucuronosyltransferase) glucuronidation of statin lactones — both mechanisms reduce hepatic statin elimination and increase systemic statin exposure, substantially raising plasma statin concentrations and myopathy risk
ANSWER: E
Rationale:
This question teaches the dual pharmacokinetic mechanism of the gemfibrozil-statin interaction — one of the most clinically important and pharmacologically specific drug interactions in cardiovascular pharmacology. Gemfibrozil inhibits two distinct elimination pathways for statins: first, it inhibits OATP1B1 on the hepatocyte sinusoidal membrane, which is the primary active uptake transporter that clears statin acid forms from portal blood into hepatocytes for metabolism and biliary excretion — inhibiting OATP1B1 increases systemic statin acid exposure; second, it inhibits UGT enzymes (particularly UGT1A1 and UGT1A3) responsible for glucuronidation of statin lactone forms, which is a key elimination pathway for simvastatin, lovastatin, and atorvastatin — inhibiting glucuronidation further increases statin exposure by reducing lactone clearance. Together these two mechanisms produce large increases in statin systemic exposure and dramatically increase myopathy risk. Fenofibrate does not meaningfully inhibit OATP1B1 or UGT enzymes, which is why it does not produce the same degree of statin interaction and is the preferred fibrate for combination with statins.
Option A: Option A fabricates a PPAR-alpha muscle mechanism that is not the basis for this interaction.
Option B: Option B is incorrect — gemfibrozil is not a significant CYP3A4 inhibitor; simvastatin's CYP3A4 interactions are with azole antifungals, clarithromycin, and grapefruit juice — not gemfibrozil.
Option C: Option C fabricates a CYP2C9-mediated epoxide metabolite that does not exist.
Option D: Option D fabricates a protein-binding displacement mechanism — gemfibrozil does not produce clinically meaningful statin displacement from albumin.
21. A 67-year-old man on simvastatin 40 mg is prescribed a 14-day course of itraconazole for onychomycosis. Which of the following best explains why this combination carries a high risk of statin-induced myopathy, and which management strategy is most appropriate?
A) Itraconazole inhibits hepatic UGT glucuronidation enzymes that are the primary elimination pathway for simvastatin — UGT inhibition produces a fourfold to sixfold increase in simvastatin lactone exposure, and the appropriate management is to switch to pravastatin, which is eliminated exclusively by renal excretion and avoids this interaction
B) Itraconazole induces hepatic CYP3A4, increasing simvastatin metabolism to an active hydroxylated metabolite with direct myotoxic properties — the appropriate management is to reduce the simvastatin dose by 50% during the itraconazole course to account for the metabolic activation
C) Itraconazole is a potent CYP3A4 inhibitor — simvastatin is a CYP3A4-dependent substrate, and co-administration with a potent CYP3A4 inhibitor produces large increases in simvastatin systemic exposure that substantially increase myopathy risk; simvastatin should be temporarily withheld during the itraconazole course, or the patient should be switched to a statin not dependent on CYP3A4 (such as rosuvastatin, pravastatin, or fluvastatin)
D) Itraconazole inhibits OATP1B1 hepatic uptake transporters — simvastatin is an OATP1B1 substrate, and transporter inhibition is the primary mechanism of the azole-statin interaction; fenofibrate should be added to competitively restore OATP1B1 transport activity during the itraconazole course
E) Itraconazole and simvastatin share a common renal elimination pathway via the P-glycoprotein (P-gp) efflux transporter in the proximal tubule — competitive inhibition of P-gp by itraconazole reduces simvastatin renal clearance and increases plasma simvastatin concentrations by 60–80%, a modest increase that requires no dose adjustment in patients with normal renal function
ANSWER: C
Rationale:
This question tests knowledge of one of the highest-risk drug interactions in statin pharmacology. Simvastatin and lovastatin are extensively metabolized by CYP3A4 — both in the intestinal wall during first-pass absorption and in the liver. When a potent CYP3A4 inhibitor such as itraconazole, ketoconazole, clarithromycin, or erythromycin is co-administered, CYP3A4-mediated metabolism of simvastatin is dramatically reduced, producing very large increases in simvastatin systemic exposure — increases of 10-fold or greater have been documented with itraconazole and simvastatin. These concentration increases translate directly into markedly elevated myopathy risk. The FDA has issued specific label restrictions: concomitant use of simvastatin with itraconazole, ketoconazole, posaconazole, voriconazole, and clarithromycin is contraindicated or strongly discouraged. The appropriate management is to temporarily withhold simvastatin during the 14-day itraconazole course, or — if statin therapy cannot be interrupted — to switch to a statin that is not CYP3A4-dependent: rosuvastatin is metabolized primarily by CYP2C9 (minor), pravastatin undergoes sulfation and is largely non-CYP, and fluvastatin is a CYP2C9 substrate.
Option A: Option A incorrectly attributes the interaction to UGT inhibition — azole antifungals are CYP3A4 inhibitors, not UGT inhibitors, and pravastatin is not eliminated exclusively by renal excretion.
Option B: Option B inverts the mechanism — itraconazole inhibits CYP3A4, it does not induce it.
Option D: Option D incorrectly attributes the azole-statin interaction to OATP1B1 inhibition — this is the mechanism of the gemfibrozil interaction; azole antifungals are not clinically significant OATP1B1 inhibitors.
Option E: Option E fabricates a renal P-gp elimination pathway for simvastatin — simvastatin undergoes negligible renal elimination and P-gp tubular secretion is not the relevant interaction mechanism.
22. A 55-year-old woman is initiated on atorvastatin 40 mg for primary prevention based on a 10-year ASCVD risk of 13% and LDL-C of 158 mg/dL. She is otherwise healthy with no drug interactions or comorbidities. When should her first follow-up fasting lipid panel be obtained to assess treatment response?
A) At 2 weeks after initiation — atorvastatin reaches pharmacokinetic steady state within 7 days and produces its maximum LDL-C lowering effect by 14 days, so a 2-week lipid panel captures the full therapeutic response and allows earlier dose adjustment if the LDL-C target has not been met
B) At 6 months after initiation — obtaining a lipid panel earlier than 6 months does not reflect the true steady-state lipid effect of statins because hepatic LDL receptor upregulation requires 4–6 months to reach its maximum expression level, and earlier measurements systematically underestimate the eventual LDL-C reduction
C) At 24 months after initiation — in a low-risk primary prevention patient with no comorbidities, the 2018 ACC/AHA guideline recommends confirming therapeutic response at 2 years to allow sufficient time for lifestyle factors to contribute to LDL-C lowering alongside pharmacological therapy
D) At 4–12 weeks after initiation — this interval allows sufficient time for the full pharmacological LDL-C lowering effect to be established while providing early feedback on treatment response, adherence, and whether dose adjustment or additional therapy is needed; once stable, annual lipid monitoring is appropriate
E) No follow-up lipid panel is required in primary prevention patients on standard-dose statin therapy — the average LDL-C reduction from atorvastatin 40 mg is well-established at 43–50%, and this predictable response makes individual lipid monitoring unnecessary except in patients who report symptoms or request reassurance
ANSWER: D
Rationale:
This question establishes the correct monitoring interval for lipid response after statin initiation — a practical prescribing skill that closes the loop between drug initiation and treatment optimization. The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol recommends reassessing the fasting lipid panel at 4–12 weeks after statin initiation or dose change. This interval is chosen for two reasons: first, statins produce their full pharmacological LDL-C lowering effect within approximately 4 weeks of initiation as hepatic LDL receptor upregulation reaches a new steady state — earlier measurement risks underestimating the response; second, measuring within 12 weeks provides timely information about whether the target LDL-C reduction has been achieved, whether the patient is adherent, and whether dose escalation or addition of ezetimibe is needed. This interval also captures early adverse effects (new aminotransferase elevations, new muscle symptoms) within a clinically actionable timeframe. Once the response is confirmed as stable and the patient is tolerating therapy, annual lipid monitoring is appropriate.
Option A: Option A is incorrect — the 2-week interval is too early; while atorvastatin does reach pharmacokinetic steady state quickly, some patients show continued LDL-C lowering between 2 and 4 weeks as hepatic LDL receptor expression continues to increase.
Option B: Option B is incorrect — 6 months is longer than necessary; the full LDL-C lowering effect is established within 4 weeks, not 4–6 months.
Option C: Option C is incorrect — a 24-month interval is never recommended for initial response assessment; this would leave subtherapeutic patients undetected for two years.
Option E: Option E is incorrect — individual lipid monitoring is essential because inter-patient variability in statin response is substantial, adherence cannot be assumed, and the achieved LDL-C reduction (not the expected average reduction) is what matters for clinical decision-making.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.